Author(s):
Pallab Mandal, Pradip Kundu, Soumya Chakraborty, Rakesh Bera, Nilendra Chatterjee, Sourav Poddar, D.P. Ghosh, Tapan Kumar Pal
Email(s):
souravpoddarsxc@gmail.com , profpaltk@gmail.com
DOI:
10.52711/0974-360X.2022.00693 
Address:
Pallab Mandal1, Pradip Kundu2, Soumya Chakraborty1, Rakesh Bera1, Nilendra Chatterjee1, Sourav Poddar3, D.P. Ghosh2, Tapan Kumar Pal1*
1TAAB Biostudy Services, Jadavpur, Kolkata 700032, India.
2Albert David Limited, Block-D, 3rd Floor, Gillander House, 8, Netaji Subhas Road, Kolkata - 700001, India.
3National Institute of Technology, Tiruchirappalli, Tamil Nadu – 620015.
*Corresponding Author
Published In:
Volume - 15,
Issue - 9,
Year - 2022
ABSTRACT:
The phosphocholine and phospholipid that is hexadecyl monoester of phosphocholine (alkyl phospholipid) is a miltefosine drug used to treat all types of leishmaniasis. It is a broad-spectrum antimicrobial, anti-leishmanial, anti-cancer phospholipid drug. It is used for the treatment of breast cancer and cutaneous metastasis. This present study of miltefosine was given to develop. It validated the analytical method by LC-MS/MS (API-2000). It will be applied to the estimation of miltefosine from its solubility sample, force degradation sample, dissolution sample, and impurity analysis. The calibration concentrations of miltefosine were 125, 250, 500, 1000, 2000, and 4000 ng/ml which accuracy was 90.903 – 109.077% and reported stability was 90.71- 97.99%, 92.04 – 98.02%, 90.00 – 95.52%, 89.72 – 98.54% for freeze-thaw, short term, benchtop, autosampler stability respectively. The developed method for determining and quantifying miltefosine in the sample was also validated as per the US-FDA and EMA guidelines. The validation parameters found within the specified regulatory limit, hence acceptable. The present method also has a short run time (6.00 min). The method is simple, specific, highly selective, sensitive, and reproducible.
Cite this article:
Pallab Mandal, Pradip Kundu, Soumya Chakraborty, Rakesh Bera, Nilendra Chatterjee, Sourav Poddar, D.P. Ghosh, Tapan Kumar Pal. Analytical Method Development and Validation of Trimethylazanium containing Anti-leishmanial Phospholipid Drug Miltefosine by Liquid Chromatography Quadruple Tandem Mass Spectrometry (LC-ESI-MS/MS) API-2000. Research Journal of Pharmacy and Technology. 2022; 15(9):4128-4. doi: 10.52711/0974-360X.2022.00693
Cite(Electronic):
Pallab Mandal, Pradip Kundu, Soumya Chakraborty, Rakesh Bera, Nilendra Chatterjee, Sourav Poddar, D.P. Ghosh, Tapan Kumar Pal. Analytical Method Development and Validation of Trimethylazanium containing Anti-leishmanial Phospholipid Drug Miltefosine by Liquid Chromatography Quadruple Tandem Mass Spectrometry (LC-ESI-MS/MS) API-2000. Research Journal of Pharmacy and Technology. 2022; 15(9):4128-4. doi: 10.52711/0974-360X.2022.00693 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-9-53
REFERENCES:
1. Alvar J, Yactayo S, Bern C. Leishmaniasis, and poverty. Trends Parasitol [Internet]. 2006;22(12):552–7. Available from: https://www.sciencedirect.com/science/article/abs/pii/S147149220600239X
2. Croft SL, Engel J. Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg [Internet]. 2006;100:S4–8. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0035920306001970
3. Croft SL, Snowdon D, Yardley V. The activities of four anti-cancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei. J Antimicrob Chemother [Internet]. 1996;38(6):1041–7. Available from: https://academic.oup.com/jac/article/38/6/1041/731885
4. Keenan, Joanna, Dallenbach, Violaine, Moss I. Patient access to miltefosine in developing countries not secure despite award of US FDA PRV sold for USD 125 million [Internet]. BMJ. 2014 [cited 2020 Oct 2]. p. 1–5. Available from: https://dndi.org/press-releases/2014/pr-miltefosine-prv/
5. Escobar P, Matu S, Marques C, Croft SL. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine), and amphotericin B. Acta Trop [Internet]. 2002;81(2):151–7. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0001706X01001978
6. Times of India. Brainstorming amoebae found in Florida. EiSamay.com [Internet]. 2016 Aug 24;1–4. Available from: https://eisamay.indiatimes.com/world/brain-eating-amoeba-found-in-florida/articleshow/53841197.cms
7. Times of India. Beware of brain-eating bug. Times of India [Internet]. 2016 Jan 28;1–4. Available from: https://timesofindia.indiatimes.com/city/kolkata/Beware-of-brain-eating-bug/articleshow/50752696.cms
8. Nakayama H, Loiseau PM, Bories C, Torres De Ortiz S, Schinini A, Serna E, et al. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother [Internet]. 2005;49(12):4950–6. Available from: https://aac.asm.org/content/49/12/4950
9. Neuber H. Leishmaniasen. JDDG - J Ger Soc Dermatology [Internet]. 2008 [cited 2020 Oct 2];6(9):754–65. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1610-0387.2008.06809.x
10. Vinson R. Application for inclusion of miltefosine on who model list of essential medicines. [Internet]. Barbados; 2010. Available from: https://www.who.int/selection_medicines/committees/expert/18/applications/Miltefosine_application.pdf?ua=1
11. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med [Internet]. 2002;347(22):1739–46. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa021556#:~:text=Oral miltefosine is an effective,are resistant to current agents.
12. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet [Internet]. 1998;352(9143):1821–3. Available from: https://doi.org/10.1016/S0140-6736(98)04367-0
13. WHO WHO. Leishmaniasis in the WHO European region [Internet]. World Health Organisation. Denmark; 2014. Available from: https://www.euro.who.int/__data/assets/pdf_file/0007/246166/Fact-sheet-Leishmaniasis-Eng.pdf?ua=1
14. Food and Drug Administration (FDA). Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) Guidance for Industry. Bioanal Method Valid [Internet]. 2018;1–44. Available from: www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
15. European Medicines Agency. Bioanalytical method validation [Internet]. London; 2011. Available from: https://www.ema.europa.eu/en/bioanalytical-method-validation
16. (CDER), U.S. Department of Health and Human Services Food and DA for DE and R, Research USD of H and HS and DA for DE and. Bioavailability, and BioequivalenceStudies for Orally AdministeredDrug Products — General Considerations [Internet]. Rockville, MD 20852; 2002. Available from: https://www.fda.gov/files/drugs/published/Guidance-for-Industry-Bioavailability-and-Bioequivalence-Studies-for-Orally-Administered-Drug-Products---General-Considerations.PDF